What pre‑operative labs are needed for patients on GLP‑1 therapy?

Understanding the Need for GLP‑1 Pre‑Operative Labs

Glucagon‑like peptide‑1 (GLP‑1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have become mainstays in the management of type 2 diabetes and obesity. Their powerful effects on blood glucose, weight, and cardiovascular health make them attractive options for many patients. However, these same mechanisms can also influence peri‑operative physiology. Conducting a thorough surgery screening that includes appropriate blood work is essential to minimize intra‑operative complications and promote a smooth recovery.

In this article we outline a comprehensive clinical checklist of laboratory tests that should be ordered before any surgical procedure for patients taking GLP‑1 therapy. The recommendations are based on current clinical guidelines, expert consensus, and the pharmacologic profile of GLP‑1 agonists.

Why GLP‑1 Therapy Affects Pre‑Operative Testing

GLP‑1 receptor agonists exert several physiologic actions that intersect with surgical risk factors:

• Glycemic modulation: They lower fasting glucose and HbA1c, but also delay gastric emptying, which can affect anesthesia induction and postoperative nutrition.
• Renal considerations: Many GLP‑1 agents are partially excreted by the kidneys; impaired renal function can lead to drug accumulation.
• Cardiovascular impact: While generally cardioprotective, they may cause modest changes in heart rate and blood pressure.
• Potential gastrointestinal side effects: Nausea, vomiting, and slowed gastric motility can complicate pre‑operative fasting protocols.

Because of these effects, a focused set of labs helps the surgical team assess readiness, adjust medication timing, and anticipate postoperative needs.

Core Laboratory Tests for GLP‑1 Patients

The following tests constitute the baseline blood work panel for most surgical candidates on GLP‑1 therapy. Additional tests may be ordered based on comorbidities or the type of surgery.

1. Glycemic Control Panel

1. Fasting Plasma Glucose (FPG): Confirms current glucose levels and helps decide whether to hold the GLP‑1 medication on the day of surgery.
2. Hemoglobin A1c (HbA1c): Provides a 2‑3 month average of glucose control; values >8 % may signal the need for tighter peri‑operative management.
3. Fructosamine (optional): Useful for short‑term glucose trends if the surgery is imminent and HbA1c is not reflective of recent changes.

2. Renal Function Assessment

1. Serum Creatinine and Estimated Glomerular Filtration Rate (eGFR): Many GLP‑1 agonists (e.g., Ozempic, Wegovy) require dose adjustments or are contraindicated when eGFR falls below 30 mL/min/1.73 m².
2. Blood Urea Nitrogen (BUN): Helps differentiate prerenal from intrinsic renal issues.

3. Hepatic Panel

1. ALT, AST, Alkaline Phosphatase, and Bilirubin: Although GLP‑1 drugs are not primarily hepatically cleared, liver disease can affect overall metabolism and anesthesia risk.

4. Complete Blood Count (CBC)

1. Hemoglobin/Hematocrit: Detects anemia, which may increase peri‑operative transfusion risk.
2. White Blood Cell Count (WBC): Identifies infection or inflammation that could postpone elective surgery.
3. Platelet Count: Essential for assessing bleeding risk.

5. Electrolyte and Acid‑Base Panel

1. Sodium, Potassium, Chloride, Bicarbonate: GLP‑1 agents can cause mild nausea and vomiting, potentially leading to electrolyte disturbances.
2. Serum Calcium and Magnesium: Important for cardiac stability during anesthesia.

6. Coagulation Profile

1. Prothrombin Time (PT) / INR and Activated Partial Thromboplastin Time (aPTT): While GLP‑1 drugs do not directly affect clotting, many surgical patients are on anticoagulants; baseline values guide peri‑operative management.

7. Thyroid Function (Selective)

If the patient has a known thyroid disorder or the surgery involves the neck region, a TSH test is advisable. GLP‑1 therapy does not typically alter thyroid hormones, but baseline data are useful for comprehensive screening.

Putting the Labs into a Clinical Checklist

Below is a practical checklist that surgical teams can integrate into electronic health records or paper charts. Use it as a guide to ensure no critical test is missed.

• Confirm patient is on a GLP‑1 agonist (Ozempic, Wegovy, Mounjaro, Zepbound).
• Order the glycemic control panel (FPG, HbA1c, optional fructosamine).
• Obtain renal function tests (Serum Creatinine, eGFR, BUN).
• Run a comprehensive hepatic panel.
• Collect a CBC with differential.
• Check electrolytes and bicarbonate.
• Perform PT/INR and aPTT.
• Consider TSH if indicated.
• Review results with anesthesia and endocrine teams.
• Decide on timing of the last GLP‑1 dose (often held the morning of surgery).

Special Considerations for Different Types of Surgery

While the core panel applies broadly, certain procedures demand extra attention:

Major Abdominal or Gastrointestinal Surgery

Because GLP‑1 agonists delay gastric emptying, surgeons may wish to confirm gastrointestinal motility through a pre‑operative ultrasound or consider a shorter fasting window. Additional labs such as serum albumin can gauge nutritional status.

Cardiothoracic Surgery

Patients with underlying heart disease should have a recent electrocardiogram (ECG) and possibly a BNP level, though these are not traditional labs, they complement the blood work for risk stratification.

Orthopedic or Joint Replacement Procedures

Bone health markers (e.g., vitamin D, calcium) are useful, especially if prolonged GLP‑1 therapy has been associated with weight loss and potential changes in bone density.

Timing of Lab Draws and Medication Management

Optimal timing ensures accurate interpretation:

• Draw labs within 30 days of the scheduled surgery; for high‑risk cases, repeat within 7 days.
• Most clinicians advise holding the GLP‑1 agonist on the day of surgery, especially if the patient will be NPO (nil per os). This reduces the risk of intra‑operative nausea and delayed gastric emptying.
• Resume the medication post‑operatively once the patient tolerates oral intake and there are no contraindications.

Integrating the Checklist into an Electronic Health Record (EHR)

Embedding the above list into an EHR order set streamlines the process:

1. Create a “GLP‑1 Pre‑Operative Labs” order set that auto‑populates all required tests.
2. Attach decision‑support alerts reminding clinicians to hold the GLP‑1 dose the morning of surgery.
3. Link the order set to the anesthesia and surgical planning modules for seamless communication.

Standardizing the workflow reduces missed labs, improves patient safety, and aligns with best practice guidelines.

Getting Started with GLP‑1

If you are considering GLP‑1 therapy for weight management or diabetes control, the first step is to verify eligibility. A licensed online provider can evaluate your medical history, discuss potential benefits, and prescribe the appropriate medication. To begin this process, you can check your eligibility here. Once you start a GLP‑1 agonist, keep the pre‑operative laboratory checklist handy for any future surgical planning.

Frequently Asked Questions

Do I need to stop my GLP‑1 medication before every surgery?

In most cases, the medication is held the morning of the procedure to reduce the risk of nausea and delayed gastric emptying. However, the decision should be individualized based on the type of surgery, the patient’s glycemic control, and the surgeon’s preference.

What if my kidney function is borderline?

If eGFR is between 30‑45 mL/min/1.73 m², many GLP‑1 agents require dose reduction or may be contraindicated. Discuss the results with your endocrinologist; they may recommend an alternative therapy or close monitoring.

Can the pre‑operative labs detect complications from GLP‑1 therapy?

While labs cannot directly identify drug‑related complications, they highlight physiologic changes (e.g., electrolyte shifts, anemia) that could be exacerbated by GLP‑1 therapy. Early detection allows clinicians to modify peri‑operative plans accordingly.

Is there a risk of hypoglycemia during surgery while on GLP‑1 agonists?

GLP‑1 agents have a low intrinsic risk of hypoglycemia, especially when used without concomitant insulin or sulfonylureas. Nonetheless, intra‑operative glucose monitoring is recommended, and the medication may be paused to further minimize any risk.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about medication, surgery, or laboratory testing.